ZYDUSLIFE Zydus Lifesciences Ltd Disposals and divestitures Announcement 2023 - Asset Transfer Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has completed the asset transfer of CUTX-101, a copper histidinate product candidate for the treatment of Menkes disease, from Cyprium Therapeutics..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd